Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Premier Specialists, Australia

Criteria

Inclusion Criteria:

• 18 years of age or older

• Diagnosis of vitiligo

• Clinically stable vitiligo: defined as no new vitiligo patches and no enlargement of existing patches in previous 3 months.

• Able to provide voluntary, written, informed consent

Exclusion Criteria:

• Clinically active vitiligo: defined as new vitiligo patches or enlargement of existing patches in previous 3 months

• Concurrent skin disease in the study area

• Immunocompromise

• Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose.